TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

New temporary pacing system for TAVR launches in US
New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.
AI-powered EHR alerts make a world of difference for cardiologists, heart patients
AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.
PCI before TAVR? In older CAD patients, deferral may be the best approach
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves
The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.

The SoloPace Fusion Temporary Pacing System from Solo Pace Inc. is deigned to eliminate the need for right ventricular (RV) lead placement, which requires the added procedural step to gaining venous access. This can cut procedure time and mitigate possible complication risks. For interventional cardiologists using improvised left ventricular (LV) pacing, this system can replace ad-hoc clip assemblies, subcutaneous needles and exposed wire connections, which are known sources of inconsistent pace capture.

New temporary pacing system for TAVR launches in US

New pacing system is designed to streamline TAVR cath lab workflows, cut procedural steps and increase reliability.

AI-powered EHR alerts make a world of difference for cardiologists, heart patients

AI can help care teams identify heart patients who would benefit from TAVR or another life-changing valve intervention.

Michiel Voskuil, MD, PhD, an interventional cardiologist and professor at University Medical Center Utrecht in the Netherlands, presented his team’s data on the ACC.26 stage.

PCI before TAVR? In older CAD patients, deferral may be the best approach

Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.

Adam Greenbaum, MD, presents late-breaking data at ACC.26.

New stroke prevention device for TAVR holds its own in head-to-head battle with Sentinel

A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.

When heart patients can’t wait: Urgent TAVR with self-expanding vs. balloon-expandable valves

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities.

Cleveland Clinic launches partnership focused on AI-powered TAVR planning

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations.

Acute kidney injury after TAVR: Key risk factors every cardiologist should know

Multiple studies have linked acute kidney injury after TAVR to a heightened risk of short- and long-term mortality.

FDA approves JenaValve TAVR system for aortic regurgitation

The Trilogy Transcatheter Heart Valve System is the first TAVR device approved by the FDA to treat severe aortic regurgitation. Until now, interventional cardiologists have had to settle for the off-label use of TAVR valves built for treating aortic stenosis.